Contrasting Exicure (NASDAQ:XCUR) & Protalix BioTherapeutics (NYSE:PLX)

Protalix BioTherapeutics (NYSE:PLX – Get Free Report) and Exicure (NASDAQ:XCUR – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Protalix BioTherapeutics and Exicure, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protalix BioTherapeutics 0 0 1 0 3.00
Exicure 1 0 0 0 1.00

Protalix BioTherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 315.94%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Exicure.

Insider and Institutional Ownership

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Protalix BioTherapeutics and Exicure”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protalix BioTherapeutics $84.69 million 2.87 $8.31 million $0.25 11.54
Exicure $500,000.00 13.76 -$4.95 million ($1.32) -0.80

Protalix BioTherapeutics has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Protalix BioTherapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.83, suggesting that its stock price is 283% more volatile than the S&P 500.

Profitability

This table compares Protalix BioTherapeutics and Exicure’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics -21.03% -30.89% -11.74%
Exicure N/A -237.91% -61.98%

Summary

Protalix BioTherapeutics beats Exicure on 8 of the 14 factors compared between the two stocks.

About Protalix BioTherapeutics

(Get Free Report)

Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.

About Exicure

(Get Free Report)

Exicure, Inc. is a biotechnology company historically focused on developing nucleic acid-based therapeutics. Its research has centered on spherical nucleic acid (SNA) technology, a platform designed to deliver genetic material into cells and influence disease-related gene activity. The company has pursued potential treatments for conditions including rare genetic disorders and cancer. Its work has included research into therapies intended to address diseases with limited treatment options. Exicure was based in Chicago, Illinois.

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.